Alistair is a seasoned pharmaceutical services executive with more than 25 years of experience in the industry, across manufacturing, consultancy, business and corporate development, data management, clinical and commercial operations. Until April 2022 Alistair was CEO of the industry leading, integrated CRO Syneos Health Inc (NASDAQ, SYNH). a role which he held for 6 years. Syneos was the result of a combination of inVentiv Health and INC Research in 2017, of which Alistair was CEO. Alistair led the merger that formed Syneos, bringing together approximately 29,000 employees serving customers in 110 countries with innovative, end-to-end solutions to accelerate their clinical development and commercialisation timelines. Prior to becoming CEO of INC Research, Alistair led multiple functions including Global Business Development and Marketing, Alliances Development and Delivery, Global Oncology, and Clinical Development Services.
Alistair has served as Chair of ACRO, the Association of Clinical Research Organisations, having been on its board for approximately seven years, and is Non-Executive Director of the Medicines Discovery Catapult.
Alistair received his Masters degree from Cranfield University, and Batchelors degree from Plymouth University.
Experienced senior executive and entrepreneur with many years of experience in drug discovery, company formation, financing, growth and exit. Neil has previously founded both biotech and contract research organisations. As founder of KWS BioTest, Neil grew a CRO from inception to sale, providing both scientific and commercial leadership. He has also been Director of Immunology at Charles River Laboratories, Director of Strategic Alliances at the Elizabeth Blackwell Institute for Health Research and Chairman of the BSI. His commercial experience is founded on a strong scientific track record as Professor of Immunology at the University of Bristol. Neil is passionate about supporting entrepreneurs to build businesses that make a difference to patients’ lives.
Robin Brown is the Chairman of Nexus BioQuest and brings experience from nearly every sector of private healthcare innovation. He has held senior positions in biotech, big pharma, contract research and venture capital/private equity investment. Robin is currently Chairman of the Medicines Discovery Catapult and is a committee member of the UCL Technology Fund managed by Albion Capital. Recently he was CEO of KWS Biotest until its acquisition by Charles River Laboratories in 2018. Previously he spent eight years as a venture partner with Advent International. His biotechnology experience, while living in Belgium, was as CSO of Devgen (acquired by Syngenta) and Galapagos.
Will is the Chief Executive Officer of Nexus BioQuest and brings over 20 years experience working in commercial science positions at companies including Zeneca, Syngenta, KWS BioTest, Charles River and Nexus BioQuest. Originally trained as a molecular biologist he has held a wide range of positions from Research Scientist, Team Leader, British Army Officer, Project Manager, Chief Operations Officer and Site Director.He holds both a BSc in Biotechnology and Master of Business Administration with a specialism in innovation. The main elements brought to Nexus BioQuest include experience growing a start up to acquisition, leadership in complex environments and projects, fiduciary responsibility to create a stable business and management of high growth operations.